OBJECTIVE: To compare the validity of three currently used chronic myeloid leukemia (CML) scoring systems (Sokal CML prognostic scoring system, Hasford prognostic scoring system, and EUTOS prognostic scoring system) in chronic phase CML (CP-CML) patients. METHODS: One hundred and thirteen CP-CML patients taking hydroxyurea, interferon or imatinib were enrolled in this study. All patients were stratified into different groups according to each scoring system and different therapies respectively. And overall survival (OS) rates were observed and compared among different groups. RESULTS: Three scoring systems were effective predictors of OS in CP-CML patients, and EUTOS scoring system may predict more validly. Hasford scoring system was well correlated with Sokal and EUTOS scores (r=0.792, P<0.01 and r=0.624, Plt;0.01). The correlation between Sokal and EUTOS scores was relatively weak (r=0.508, Plt;0.01). Despite imatinib's marked effect in prolonging survival of CML patients, it was incapable of prolonging survival in Sokal, Hasford and EUTOS high- risk patients. CONCLUSION: EUTOS prognostic scoring system may predict better than Sokal and Hasford systems in CML patients. Classification of patients based on the three scoring systems may assist in the choice of appropriate therapy for CML.
OBJECTIVE: To compare the validity of three currently used chronic myeloid leukemia (CML) scoring systems (Sokal CML prognostic scoring system, Hasford prognostic scoring system, and EUTOS prognostic scoring system) in chronic phase CML (CP-CML) patients. METHODS: One hundred and thirteen CP-CMLpatients taking hydroxyurea, interferon or imatinib were enrolled in this study. All patients were stratified into different groups according to each scoring system and different therapies respectively. And overall survival (OS) rates were observed and compared among different groups. RESULTS: Three scoring systems were effective predictors of OS in CP-CMLpatients, and EUTOS scoring system may predict more validly. Hasford scoring system was well correlated with Sokal and EUTOS scores (r=0.792, P<0.01 and r=0.624, Plt;0.01). The correlation between Sokal and EUTOS scores was relatively weak (r=0.508, Plt;0.01). Despite imatinib's marked effect in prolonging survival of CMLpatients, it was incapable of prolonging survival in Sokal, Hasford and EUTOS high- risk patients. CONCLUSION: EUTOS prognostic scoring system may predict better than Sokal and Hasford systems in CMLpatients. Classification of patients based on the three scoring systems may assist in the choice of appropriate therapy for CML.
Authors: Jimena Ylescas-Soria; Alfredo H de la Torre-Lujan; Luis A Herrera; Daniela Miranda; Flavio Grimaldo; Silvia Rivas; Eduardo Cervera; Abelardo Meneses-García; Fidias E Leon-Sarmiento; Diddier Prada Journal: Cancer Med Date: 2019-05-02 Impact factor: 4.452